RT Journal Article SR Electronic T1 Post-marketing surveillance of enalapril: experience in 11 710 hypertensive patients in general practice JF The Journal of the Royal College of General Practitioners JO J R Coll Gen Pract FD British Journal of General Practice SP 346 OP 349 VO 37 IS 301 A1 Warren D. Cooper A1 David Sheldon A1 Derek Brown A1 Graham R. Kimber A1 Valerie L. Isitt A1 William J.C. Currie YR 1987 UL http://bjgp.org/content/37/301/346.abstract AB Post-marketing surveillance in general practice represents an important part of the monitoring of adverse events associated with newly introduced drugs. Such a study of the angiotensin-converting enzyme inhibitor enalapril maleate has been undertaken in 11 710 patients with essential hypertension. Serious adverse events occurred in 1.7% of patients, though most of these were not thought to be related to the treatment. The incidence rates of death (0.09%), stroke (0.11%) and myocardial infarction (0.15%) were compatible with rates predicted from age, sex and blood pressure considerations. Other events reported were hypotension (0.3%), angioneurotic oedema (0.03%), rash (0.5%), taste disturbance (0.2%) and cough (1.0%). The degree of blood pressure reduction attained was similar to that previously reported from pre-marketing development studies, as was the overall nature and frequency of both serious and non-serious adverse events. The most frequently reported event during enalapril therapy was of an improvement in well-being (19.8%).